Trial Profile
A Proof-of-Concept Clinical Research Study of Efavirenz in Patients With Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Feb 2022
Price :
$35
*
At a glance
- Drugs Efavirenz (Primary)
- Indications Alzheimer's disease
- Focus Pharmacodynamics; Proof of concept
- Acronyms EPAD
- 28 Jan 2022 Status changed from active, no longer recruiting to completed.
- 13 Dec 2021 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.
- 13 Dec 2021 Planned primary completion date changed from 31 Jul 2021 to 31 Jul 2022.